Sexually transmitted Chlamydia trachomatis infections remain common globally and most frequently are asymptomatic. The 2025 European C. trachomatis guideline provides up-to-date guidance regarding indications for testing and treatment of C. trachomatis infections. It includes advice on urogenital and extragenital C. trachomatis testing including the use of self-collected specimens; recommendation to use only validated NAATs for diagnosis; and recommendation to treat all C. trachomatis infections with doxycycline as first line in preference to single-dose azithromycin regimens. The absence of evidence and limited value of broad screening in asymptomatic populations for C. trachomatis infections is also discussed.
StammWE. Chlamydia trachomatis infections of the adults. In: HolmesKKSparlingPF, et al. (eds) Sexually transmitted diseases. 4th edition. New York, NY: McGraw Hill, 2008. Chapter 32.
3.
DielissenPWTeunissenDAMLagro-JanssenALM. Chlamydia prevalence in the general population: is there a sex difference? A systematic review. BMC Infect Dis2013; 13: 534.
4.
MitchellPMWhiteLFRahimiLM, et al.335 predictors of gonorrhea and Chlamydia in emergency department patients. Ann Emerg Med2012; 60: S119.
5.
MolanoMMeijerCJWeiderpassE, et al.The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis2005; 191: 907–916.
6.
MorreSAvan den BruleAJRozendaalL, et al.The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS2002; 13(Suppl 2): 12–18.
7.
BevanCDJohalBJMumtazG, et al.Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. Br J Obstet Gynaecol1995; 102: 407–414.
8.
MorcosRFrostNHnatM, et al.Laparoscopic versus clinical diagnosis of acute pelvic inflammatory disease. J Reprod Med1993; 38: 53–56.
9.
Recommendations arising from the 31st study group: the prevention of pelvic infection. In TempletonAA (Eds.), London, UK: RCOG Press, 1996, 267–270.
10.
KentCKChawJKWongW, et al.Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis2005; 41: 67–74.
11.
BoisvertJFKoutskyLASuchlandRJ, et al.Clinical features of Chlamydia trachomatis rectal infection by serovar among homosexually active men. Sex Transm Dis1999; 26: 392–398.
12.
QuinnTCGoodellSEMkrtichianE, et al.Chlamydia trachomatis proctitis. N Engl J Med1981; 305: 195–200.
13.
DewartCMBernsteinKTDeGrooteNP, et al.Prevalence of rectal chlamydial and gonococcal infections: a systematic review. Sex Transm Dis2018; 45: 287–293.
14.
ChandraNLBroadCFolkardK, et al.Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and metaanalysis. Sex Transm Infect2018; 94: 320–326.
15.
van LiereGAHoebeCJWolffsPF, et al.High co-occurrence of anorectal chlamydia with urogenital chlamydia in women visiting an STI clinic revealed by routine universal testing in an observational study; a recommendation towards a better anorectal chlamydia control in women. BMC Infect Dis2014; 14: 274.
16.
van RooijenMSvan der LoeffMFMorréSA, et al.Spontaneous pharyngeal Chlamydia trachomatis RNA clearance. A cross-sectional study followed by a cohort study of untreated STI clinic patients in Amsterdam, The Netherlands. Sex Transm Infect2015; 91: 157–164.
17.
EversYJDukers-MuijrersNHTMvan LiereGAFS, et al.Pharyngeal Chlamydia trachomatis in men who have sex with men (MSM) in The Netherlands: a large retrospective cohort study. Clin Infect Dis2022; 74: 1480–1484.
18.
EversYJvan LiereGAFSDukers-MuijrersNHTM, et al.Routine universal testing versus selective or incidental testing for oropharyngeal Chlamydia trachomatis in women in The Netherlands: a retrospective cohort study. Lancet Infect Dis2022; 22: 552–561.
19.
ParkJMarcusJLPandoriM, et al.Sentinel surveillance for pharyngeal chlamydia and gonorrhea among men who have sex with men--San Francisco, 2010. Sex Transm Dis2012; 39: 482–484.
20.
JonesBRAl-HussainiMKDunlopEM. Infection of the eye and the genital tract by Tric agent. Br J Vener Dis1964; 40: 19–24.
21.
HuVHHarding-EschEMBurtonMJ, et al.Epidemiology and control of trachoma: systematic review. Trop Med Int Health2010; 15: 673–691.
22.
PetrovayFNémethIBalázsA, et al.Chlamydial conjunctivitis: prevalence and serovar distribution of Chlamydia trachomatis in adults. J Med Microbiol2015; 64: 967–970.
23.
DarvilleT. Chlamydia trachomatis infections in neonates and young children. Semin Pediatr Infect Dis2005; 16: 235–244.
24.
WhiteJA. Manifestations and management of lymphogranuloma venereum. Curr Opin Infect Dis2009; 22: 57–66.
25.
de VriezeNHvan RooijenMSchim van der LoeffMF, et al.Anorectal and inguinal lymphogranuloma venereum among men who have sex with men in Amsterdam, The Netherlands: trends over time, symptomatology and concurrent infections. Sex Transm Infect2013; 89: 548–552.
26.
SaxonCHughesGIsonCUK LGV Case-Finding Group. Asymptomatic lymphogranuloma venereum in men who have sex with men, United Kingdom. Emerg Infect Dis2016; 22: 112–116.
27.
de VriesHJCde BarbeyracBde VriezeNHN, et al.2019 European guideline on the management of lymphogranuloma venereum. J Eur Acad Dermatol Venereol2019; 33: 1821–1828.
28.
Dukers-MuijrersNHTMEversYJHoebeCJPA, et al.Controversies and evidence on chlamydia testing and treatment in asymptomatic women and men who have sex with men: a narrative review. BMC Infect Dis2022; 22: 255.
29.
MårdhPA. Influence of infection with Chlamydia trachomatis on pregnancy outcome, infant health and life-long sequelae in infected offspring. Best Pract Res Clin Obstet Gynaecol2002; 16: 847–864.
30.
CurrieMJBowdenFJ. The importance of chlamydial infections in obstetrics and gynaecology: an update. Aust N Z J Obstet Gynaecol2007; 47: 2–8.
31.
BrocklehurstPRooneyG. Interventions for treating genital Chlamydia trachomatis infection in pregnancy. Cochrane Database Syst Rev1998; 1998: CD000054.
32.
MartinDHEschenbachDACotchMF, et al.Double-blind placebo-controlled treatment trial of Chlamydia trachomatis endocervical infections in pregnant women. Infect Dis Obstet Gynecol1997; 5: 10–17.
33.
MullickSWatson-JonesDBeksinskaM, et al.Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. Sex Transm Infect2005; 81: 294–302.
34.
NgassaPCEgbeJA. Maternal genital Chlamydia trachomatis infection and the risk of preterm labor. Int J Gynaecol Obstet1994; 47: 241–246.
35.
BaudDGoyGJatonK, et al.Role of Chlamydia trachomatis in miscarriage. Emerg Infect Dis2011; 17: 1630–1635.
PararasMVSkevakiCLKafetzisDA. Preterm birth due to maternal infection: causative pathogens and modes of prevention. Eur J Clin Microbiol Infect Dis2006; 25: 562–569.
38.
KovácsLNagyEBerbikI, et al.The frequency and the role of Chlamydia trachomatis infection in premature labor. Int J Gynaecol Obstet1998; 62: 47–54.
39.
DondersGGMoermanPDe WetGH, et al.The association between chlamydia cervicitis, chorioamnionitis and neonatal complications. Arch Gynecol Obstet1991; 249: 79–85.
40.
BermanSMHarrisonHRBoyceWT, et al.Low birth weight, prematurity, and postpartum endometritis. Association with prenatal cervical Mycoplasma hominis and Chlamydia trachomatis infections. JAMA1987; 257: 1189–1194.
41.
HammerschlagMR. Chlamydial and gonococcal infections in infants and children. Clin Infect Dis2011; 53(Suppl 3): S99–S102.
42.
SilvaMJFlorencioGLGabiattiJR, et al.Perinatal morbidity and mortality associated with chlamydial infection: a meta-analysis study. Braz J Infect Dis2011; 15: 533–539.
43.
McCormickMC. The contribution of low birth weight to infant mortality and childhood morbidity. N Engl J Med1985; 312: 82–90.
44.
RoursIGHammerschlagMROttA, et al.Chlamydia trachomatis as a cause of neonatal conjunctivitis in Dutch infants. Pediatrics2008; 121: e321–e326.
45.
RoursGIHammerschlagMRVan DoornumGJ, et al.Chlamydia trachomatis respiratory infection in Dutch infants. Arch Dis Child2009; 94: 705–707.
46.
WuSXYangJLiuG. A clinical study in China of neonatal conjunctivitis caused by Chlamydia trachomatis. Clin Pediatr2003; 42: 83–84.
47.
SchachterJGrossmanMSweetRL, et al.Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA1986; 255: 3374–3377.
48.
CookRLHutchisonSLØstergaardL, et al.Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med2005; 142: 914–925.
49.
WatsonEJTempletonARussellI, et al.The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review. J Med Microbiol2002; 51: 1021–1031.
50.
SkidmoreSHornerPMallinsonH. Testing specimens for Chlamydia trachomatis. Sex Transm Infect2006; 82: 272–275.
51.
SkidmoreSHornerPHerringA, et al.Vulvovaginal-swab or first-catch urine specimen to detect Chlamydia trachomatis in women in a community setting?J Clin Microbiol2006; 44: 4389–4394.
52.
ChoeHSLeeDSLeeSJ, et al.Performance of Anyplex II multiplex real-time PCR for the diagnosis of seven sexually transmitted infections: comparison with currently available methods. Int J Infect Dis2013; 17: e1134–1140.
53.
GimenesFMedinaFSAbreuAL, et al.Sensitive simultaneous detection of seven sexually transmitted agents in semen by multiplex-PCR and of HPV by single PCR. PLoS One2014; 9: e98862.
54.
KumamotoYMatsumotoTFujisawaM, et al.Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urogenital and oral specimens using the Cobas(R) 4800, APTIMA Combo 2(R) TMA, and ProbeTec ET SDA assays. Eur J Microbiol Immunol (Bp)2012; 2: 121–127.
55.
Le RoyCLe HenIClercM, et al.The first performance report for the Bio-Rad Dx CT/NG/MG assay for simultaneous detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium in urogenital samples. J Microbiol Methods2012; 89: 193–197.
56.
MushanskiLMBrandtKCoffinN, et al.Comparison of the BD Viper System with XTR Technology to the Gen-Probe APTIMA COMBO 2 assay using the TIGRIS DTS system for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens. Sex Transm Dis2012; 39: 514–517.
57.
SchachterJChowJMHowardH, et al.Detection of Chlamydia trachomatis by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised. J Clin Microbiol2006; 44: 2512–2517.
58.
van der HelmJJHoebeCJvan RooijenMS, et al.High performance and acceptability of self-collected rectal swabs for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. Sex Transm Dis2009; 36: 493–497.
59.
ChengAQianQFKirbyJE. Evaluation of the abbott RealTime CT/NG assay in comparison to the roche cobas amplicor CT/NG assay. J Clin Microbiol2011; 49: 1294–1300.
60.
AaronKJGrinerSFootmanA, et al.Vaginal swab vs urine for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis: a meta-analysis. Ann Fam Med2023; 21: 172–179.
61.
CherneskyMJangDSmiejaM, et al.Urinary meatal swabbing detects more men infected with Mycoplasma genitalium and four other sexually transmitted infections than first catch urine. Sex Transm Dis2017; 44: 489–491.
62.
DizeLAgredaPQuinnN, et al.Comparison of self-obtained penile-meatal swabs to urine for the detection of C. trachomatis, N. gonorrhoeae and T. vaginalis. Sex Transm Infect2013; 89: 305–307.
63.
Van Der PolBCherneskyMGaydosCA, et al.Multicenter comparison of nucleic acid amplification tests for the diagnosis of rectal and oropharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae infections. J Clin Microbiol2022; 60: e0136321.
64.
DoernbergSBKomarowLTranTTT, et al.Simultaneous evaluation of diagnostic assays for pharyngeal and rectal Neisseria gonorrhoeae and Chlamydia trachomatis using a master protocol. Clin Infect Dis2020; 71: 2314–2322.
65.
AdamsonPCKlausnerJD. Diagnostic tests for detecting Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and pharyngeal specimens. J Clin Microbiol2022; 60: e0021121.
DirksJAMCJanssenKHoebeCJPA, et al.Chlamydia trachomatis intra-bacterial and total plasmid copy number in clinical urogenital samples. Sci Rep2021; 11: 259.
68.
RipaTNilssonP. A variant of Chlamydia trachomatis with deletion in cryptic plasmid: implications for use of PCR diagnostic tests. Euro Surveill2006; 11: E061109.2.
69.
UnemoMSeth-SmithHMCutcliffeLT, et al.The Swedish new variant of Chlamydia trachomatis: genome sequence, morphology, cell tropism and phenotypic characterization. Microbiology2010; 156: 1394–1404.
70.
UnemoMClarkeIN. The Swedish new variant of Chlamydia trachomatis. Curr Opin Infect Dis2011; 24: 62–69.
71.
JohansenTBKløvstadHRykkvinR, et al.The ‘Finnish new variant of Chlamydia trachomatis’ escaping detection in the Aptima Combo 2 assay is widespread across Norway, june to august 2019. Euro Surveill2019; 24: 1900592.
72.
HadadRJensenJSWesthH, et al.A Chlamydia trachomatis 23S rRNA G1523A variant escaping detection in the Aptima combo 2 assay (Hologic) was widespread across Denmark in july-september 2019. APMIS2020; 128: 440–444.
73.
UnemoMHansenMHadadR, et al.Finnish new variant of Chlamydia trachomatis escaping detection in the Aptima Combo 2 assay also present in Örebro County, Sweden, may 2019. Euro Surveill2019; 24: 1900370.
74.
HokynarKRantakokko-JalavaKHakanenA, et al.The Finnish new variant of Chlamydia trachomatis with a single nucleotide polymorphism in the 23S rRNA target escapes detection by the Aptima Combo 2 test. Microorganisms2019; 7: 227.
75.
PuolakkainenMMannonenLUnemoM. The diagnostic-escape Finnish new variant of Chlamydia trachomatis first described in 2019 remains present in Finland three years after the introduction of an updated Aptima Combo 2 assay. Clin Microbiol Infect2023; 29: 658–659.
76.
ColeMJDavisGSFiferH, et al.No widespread dissemination of Chlamydia trachomatis diagnostic-escape variants and the impact of Neisseria gonorrhoeae positivity on the Aptima Combo 2 assay. Sex Transm Infect2022; 98: 366–370.
77.
JebakumarSPStoreyCLusherM, et al.Value of screening for oro-pharyngeal Chlamydia trachomatis infection. J Clin Pathol (Lond)1995; 48: 658–661.
78.
HammerschlagMRRoblinPMGellingM, et al.Use of polymerase chain reaction for the detection of Chlamydia trachomatis in ocular and nasopharyngeal specimens from infants with conjunctivitis. Pediatr Infect Dis J1997; 16: 293–297.
79.
OtaKVTamariIESmiejaM, et al.Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in pharyngeal and rectal specimens using the BD Probetec ET system, the Gen-Probe Aptima Combo 2 assay and culture. Sex Transm Infect2009; 85: 182–186.
80.
PetersRPHVerweijSPNijstenN, et al.Evaluation of sexual history-based screening of anatomic sites for Chlamydia trachomatis and Neisseria gonorrhoeae infection in men having sex with men in routine practice. BMC Infect Dis2011; 11: 203.
81.
TippleCHillSCSmithA. Is screening for pharyngeal Chlamydia trachomatis warranted in high-risk groups?Int J STD AIDS2010; 21: 770–771.
82.
MarcusJLBernsteinKTKohnRP, et al.Infections missed by urethral-only screening for chlamydia or gonorrhea detection among men who have sex with men. Sex Transm Dis2011; 38: 922–924.
83.
Van DommelenLVan TielFHOuburgS, et al.Alarmingly poor performance in Chlamydia trachomatis point-of-care testing. Clin Microbiol Infect2010; 16: S560.
84.
van der HelmJJSabajoLOGrunbergAW, et al.Point-of-care test for detection of urogenital chlamydia in women shows low sensitivity. A performance evaluation study in two clinics in Suriname. PLoS One2012; 7: e32122.
85.
LibbusMK. Chlamydia rapid test was moderately accurate for diagnosing Chlamydia infection in women. Evid Base Nurs2008; 11: 89.
86.
HislopJQuayyumZFlettG, et al.Systematic review of the clinical effectiveness and cost-effectiveness of rapid point-of-care tests for the detection of genital chlamydia infection in women and men review. Health Technol Assess2010; 14(29): 1.
87.
SkidmoreS. Poorly performing point-of-care tests for chlamydia: what can be done?Sex Transm Infect2010; 86: 330.
KellyHColtartCEMPant PaiN, et al.Systematic reviews of point-of-care tests for the diagnosis of urogenital Chlamydia trachomatis infections. Sex Transm Infect2017; 93(S4): S22–S30.
90.
van der SnoekEMOssewaardeJMvan der MeijdenWI, et al.The use of serological titres of IgA and IgG in (early) discrimination between rectal infection with non-lymphogranuloma venereum and lymphogranuloma venereum serovars of Chlamydia trachomatis. Sex Transm Infect2007; 83: 330–334.
91.
de VriesHJSmelovVOuburgS, et al.Anal lymphogranuloma venereum infection screening with IgA anti-Chlamydia trachomatis-specific major outer membrane protein serology. Sex Transm Dis2010; 37: 789–795.
92.
VerweijSPLanjouwEBaxCJ, et al.Serovar D and E of serogroup B induce highest serological responses in urogenital Chlamydia trachomatis infections. BMC Infect Dis2014; 14: 3.
93.
GijsenAPLandJAGoossensVJ, et al.Chlamydia antibody testing in screening for tubal factor subfertility: the significance of IgG antibody decline over time. Hum Reprod2002; 17: 699–703.
94.
BlackCM. Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin Microbiol Rev1997; 10: 160–184.
95.
SheRCWelchRWilsonAR, et al.Correlation of Chlamydia and Chlamydophila spp. IgG and IgM antibodies by microimmunofluorescence with antigen detection methods. J Clin Lab Anal2011; 25: 305–308.
96.
CladAFreidankHMKunzeM, et al.Detection of seroconversion and persistence of Chlamydia trachomatis antibodies in five different serological tests. Eur J Clin Microbiol Infect Dis2000; 19: 932–937.
97.
MoutonJWPeetersMFvan Rijssort-VosJH, et al.Tubal factor pathology caused by Chlamydia trachomatis: the role of serology. Int J STD AIDS2002; 13(Suppl 2): 26–29.
98.
VerkooyenRPPeetersMFvan Rijsoort-VosJH, et al.Sensitivity and specificity of three new commercially available Chlamydia trachomatis tests. Int J STD AIDS2002; 13(Suppl 2): 23–25.
99.
LandJAEversJL. Chlamydia infection and subfertility. Best Pract Res Clin Obstet Gynaecol2002; 16: 901–912.
100.
WilsonJDWallaceHELoftus-KeelingM, et al.Swab-yourself trial with economic monitoring and testing for infections collectively (systematic): Part 2. A diagnostic accuracy and cost-effectiveness study comparing rectal, pharyngeal, and urogenital samples analyzed individually, versus as a pooled specimen, for the diagnosis of gonorrhea and chlamydia. Clin Infect Dis2020; 73: e3183–e3193.
101.
WisniewskiCAWhiteJAMichelCE, et al.Optimal method of collection of first-void urine for diagnosis of Chlamydia trachomatis infection in men. J Clin Microbiol2008; 46: 1466–1469.
102.
ManginDMurdochDWellsJE, et al.Chlamydia trachomatis testing sensitivity in midstream compared with first-void urine specimens. Ann Fam Med2012; 10: 50–53.
103.
MichelCESonnexCCarneCA, et al.Chlamydia trachomatis load at matched anatomic sites: implications for screening strategies. J Clin Microbiol2007; 45: 1395–1402.
104.
LiJJangDGilchristJ, et al.Comparison of flocked and aptima swabs and two specimen transport media in the Aptima Combo 2 assay. J Clin Microbiol2014; 52: 3808–3809.
105.
BialasiewiczSWhileyDMBuhrer-SkinnerM, et al.A novel gel-based method for self-collection and ambient temperature postal transport of urine for PCR detection of Chlamydia trachomatis. Sex Transm Infect2009; 85: 102–105.
106.
GraseckASShihSLPeipertJF. Home versus clinic-based specimen collection for Chlamydia trachomatis and Neisseria gonorrhoeae. Expert Rev Anti Infect Ther2011; 9: 183–194.
107.
SextonMEBakerJJNakagawaK, et al.How reliable is self-testing for gonorrhea and chlamydia among men who have sex with men?J Fam Pract2013; 62: 70–78.
108.
SextonMBakerJPerkinsR, et al.Self-administered Neisseria gonorrhoeae and Chlamydia trachomatis testing in the pharynx and rectum among men who have sex with men in Washington, DC. Sex Transm Infect2011; 87: A74–A75.
109.
AlexanderSIsonCParryJ, et al.Self-taken pharyngeal and rectal swabs are appropriate for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in asymptomatic men who have sex with men. Sex Transm Infect2008; 84: 488–492.
110.
Holland-HallCMWiesenfeldHCMurrayPJ. Self-collected vaginal swabs for the detection of multiple sexually transmitted infections in adolescent girls. J Pediatr Adolesc Gynecol2002; 15: 307–313.
111.
FangJHusmanCDeSilvaL, et al.Evaluation of self-collected vaginal swab, first void urine, and endocervical swab specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in adolescent females. J Pediatr Adolesc Gynecol2008; 21: 355–360.
112.
SchachterJCherneskyMAWillisDE, et al.Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis2005; 32: 725–728.
113.
CherneskyMAHookEW3rdMartinDH, et al.Women find it easy and prefer to collect their own vaginal swabs to diagnose Chlamydia trachomatis or Neisseria gonorrhoeae infections. Sex Transm Dis2005; 32: 729–733.
114.
HobbsMMvan der PolBTottenP, et al.From the NIH: proceedings of a workshop on the importance of self-obtained vaginal specimens for detection of sexually transmitted infections. Sex Transm Dis2008; 35: 8–13.
115.
GaydosCAFarshyCBarnesM, et al.Can mailed swab samples be dry-shipped for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by nucleic acid amplification tests?Diagn Microbiol Infect Dis2012; 73: 16–20.
116.
DoshiJSPowerJAllenE. Acceptability of chlamydia screening using self-taken vaginal swabs. Int J STD AIDS2008; 19: 507–509.
117.
CherneskyMAJangDPortilloE, et al.Self-collected swabs of the urinary meatus diagnose more Chlamydia trachomatis and Neisseria gonorrhoeae infections than first catch urine from men. Sex Transm Infect2013; 89: 102–104.
118.
DizeLBarnesPJrBarnesM, et al.Performance of self-collected penile-meatal swabs compared to clinician-collected urethral swabs for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium by nucleic acid amplification assays. Diagn Microbiol Infect Dis2016; 86: 131–135.
119.
BerryLStanleyB. Comparison of self-collected meatal swabs with urine specimens for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men. J Med Microbiol2017; 66: 134–136.
120.
PittarasTEPapaparaskevasJHouhoulaDP, et al.Comparison of penile skin swab with intra-urethral swab and first void urine for polymerase chain reaction-based diagnosis of Chlamydia trachomatis urethritis in male patients. Sex Transm Dis2008; 35: 999–1001.
121.
CherneskyMJangDGilchristJ, et al.Head-to-head comparison of second-generation nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae on urine samples from female subjects and self-collected vaginal swabs. J Clin Microbiol2014; 52: 2305–2310.
122.
FitzhughVAHellerDS. Significance of a diagnosis of microorganisms on pap smear. J Low Genit Tract Dis2008; 12: 40–51.
123.
CherneskyMJangDPortilloE, et al.Detection of Chlamydia trachomatis in SurePath(trademark) liquid-based Pap samples using Aptima Combo 2(registered trademark), AMPLICOR(trademark) and ProbeTec(trademark) assays. Can J Infect Dis Med Microbiol2010; 21: 10A.
124.
CamusCPenarandaGKhiriH, et al.Acceptability and efficacy of vaginal self-sampling for genital infection and bacterial vaginosis: a cross-sectional study. PLoS One2021; 16: e0260021.
125.
LockhartAPsiodaMTingJ, et al.Prospective evaluation of cervicovaginal self- and cervical physician collection for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium infections. Sex Transm Dis2018; 45: 488–493.
126.
VialardFAnandALeung SooC, et al.Self-sampling strategies (with/without digital innovations) in populations at risk of Chlamydia trachomatis and Neisseria gonorrhoeae: a systematic review and meta-analyses. Sex Transm Infect2023; 99: 420–428.
127.
WardHDe VriesHJCVan De LaarM. Re-emergence of lymphogranuloma venereum in Europe and the public health response. Sex Transm Infect2011; 87: A19–A20.
128.
WardHMartinIMacdonaldN, et al.Lymphogranuloma venereum in the United Kingdom. Clin Infect Dis2007; 44: 26–32.
129.
ProchazkaMCharlesHAllenH, et al.Rapid increase in lymphogranuloma venereum among HIV-negative men who have sex with men, England, 2019. Emerg Infect Dis2021; 27: 2695–2699.
130.
Martínez-GarcíaLOrvizEGonzález-AlbaJM, et al.Rapid expansion of lymphogranuloma venereum infections with fast diversification and spread of Chlamydia trachomatis L genovariants. Microbiol Spectr2024; 12: e0285523.
131.
de VriesHJCNoriAVKiellberg LarsenH, et al.2021 European Guideline on the management of proctitis, proctocolitis and enteritis caused by sexually transmissible pathogens. J Eur Acad Dermatol Venereol2021; 35: 1434–1443.
132.
RadixAEHarrisABBelkindU, et al.Chlamydia trachomatis infection of the neovagina in transgender women. Open Forum Infect Dis2019; 6: ofz470.
133.
van den BroekIVvan BergenJEBrouwersEE, et al.Effectiveness of yearly, register based screening for chlamydia in The Netherlands: controlled trial with randomised stepped wedge implementation. BMJ2012; 345: e4316.
134.
de WitGAOverEASchmidBV, et al.Chlamydia screening is not cost-effective at low participation rates: evidence from a repeated register-based implementation study in The Netherlands. Sex Transm Infect2015; 91: 423–429.
135.
HockingJSTemple-SmithMGuyR, et al.Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial. Lancet2018; 392: 1413–1422.
136.
OakeshottPKerrySAghaizuA, et al.Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ2010; 340: c1642.
137.
ScholesDStergachisAHeidrichFE, et al.Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med1996; 334: 1362–1366.
138.
CantorADanaTGriffinJC, et al.Screening for chlamydial and gonococcal infections: updated evidence report and systematic review for the US preventive services task force. JAMA2021; 326: 957–966.
139.
van BergenJEAMHoenderboomBMDavidS, et al.Where to go to in chlamydia control? From infection control towards infectious disease control. Sex Transm Infect2021; 97: 501–506.
140.
van LiereGDukers-MuijrersNLevelsL, et al.High proportion of anorectal Chlamydia trachomatis and Neisseria gonorrhoeae after routine universal urogenital and anorectal screening in women visiting the sexually transmitted infection clinic. Clin Infect Dis2017; 64: 1705–1710.
141.
van LiereGAvan RooijenMSHoebeCJ, et al.Prevalence of and factors associated with rectal-only chlamydia and gonorrhoea in women and in men who have sex with men. PLoS One2015; 10: e0140297.
142.
GeislerWMWangCMorrisonSG, et al.The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis2008; 35: 119–123.
143.
CohenIVeilleJCCalkinsBM. Improved pregnancy outcome following successful treatment of chlamydial infection. JAMA1990; 263: 3160–3163.
144.
RyanGMJrAbdellaTNMcNeeleySG, et al.Chlamydia trachomatis infection in pregnancy and effect of treatment on outcome. Am J Obstet Gynecol1990; 162: 34–39.
145.
McGregorJAFrenchJIRichterR, et al.Cervicovaginal microflora and pregnancy outcome: results of a double-blind, placebo-controlled trial of erythromycin treatment. Am J Obstet Gynecol1990; 163: 1580–1591.
146.
HornerPJ. Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy. Sex Transm Infect2012; 88: 154–156.
147.
SandozKMRockeyDD. Antibiotic resistance in chlamydiae. Future Microbiol2010; 5: 1427–1442.
148.
WangSAPappJRStammWE, et al.Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report. J Infect Dis2005; 191: 917–923.
149.
O'NeillCESeth-SmithHMVan Der PolB, et al.Chlamydia trachomatis clinical isolates identified as tetracycline resistant do not exhibit resistance in vitro: whole-genome sequencing reveals a mutation in porB but no evidence for tetracycline resistance genes. Microbiology2013; 159: 748–756.
150.
PittRDoyleRTheilgaard ChristiansenM, et al.Whole-genome sequencing of Chlamydia trachomatis isolates from persistently infected patients. Int J STD AIDS2022; 33: 442–446.
151.
DeguchiTHatazakiKItoS, et al.Macrolide and fluoroquinolone resistance is uncommon in clinical strains of Chlamydia trachomatis. J Infect Chemother2018; 24: 610–614.
152.
VillaLBogaJAOteroL, et al.Phenotypic and genotypic antimicrobial susceptibility testing of Chlamydia trachomatis isolates from patients with persistent or clinical treatment failure in Spain. Antibiotics (Basel)2023; 12: 975.
153.
KongFYTabriziSNLawM, et al.Azithromycin versus doxycycline for the treatment of genital Chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis2014; 59: 193–205.
154.
Páez-CanroCAlzateJPGonzálezLM, et al.Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev2019; 1: CD010871.
155.
MohammadzadehFDolatianMJorjaniM, et al.Urogenital chlamydia trachomatis treatment failure with azithromycin: a meta-analysis. Int J Reprod Biomed2019; 17: 603–620.
156.
HandsfieldHH. Questioning azithromycin for chlamydial infection. Sex Transm Dis2011; 38: 1028–1029.
157.
SchwebkeJRRompaloATaylorS, et al.Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial. Clin Infect Dis2011; 52: 163–170.
158.
SenaACLensingSRompaloA, et al.Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy. J Infect Dis2012; 206: 357–365.
159.
KongFYHockingJS. Treatment challenges for urogenital and anorectal Chlamydia trachomatis. BMC Infect Dis2015; 15: 293.
160.
SteedmanNMMcMillanA. Treatment of asymptomatic rectal Chlamydia trachomatis: Is single-dose azithromycin effective?Int J STD AIDS2009; 20: 16–18.
161.
ElgalibAAlexanderSTongCYW, et al.Seven days of doxycycline is an effective treatment for asymptomatic rectal Chlamydia trachomatis infection. Int J STD AIDS2011; 22: 474–477.
162.
HathornEOpieCGooldP. What is the appropriate treatment for the management of rectal Chlamydia trachomatis in men and women?Sex Transm Infect2012; 88: 352–354.
163.
KhosropourCMDombrowskiJCBarbeeLA, et al.Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study. Sex Transm Dis2014; 41: 79–85.
164.
LauAKongFYSFairleyCK, et al.Azithromycin or doxycycline for asymptomatic rectal Chlamydia trachomatis. N Engl J Med2021; 384: 2418–2427.
165.
DombrowskiJCWierzbickiMRNewmanLM, et al.Doxycycline versus azithromycin for the treatment of rectal chlamydia in men who have sex with men: a randomized controlled trial. Clin Infect Dis2021; 73: 824–831.
166.
PeuchantOLhommeEMartinetP, et al.Doxycycline versus azithromycin for the treatment of anorectal Chlamydia trachomatis infection in women concurrent with vaginal infection (CHLAZIDOXY study): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Infect Dis2022; 22: 1221–1230.
167.
Dukers-MuijrersNHTMWolffsPFGDe VriesH, et al.Treatment effectiveness of azithromycin and doxycycline in uncomplicated rectal and vaginal Chlamydia trachomatis infections in women: a multicentre observational study (FemCure). Clin Infect Dis2019; 69: 1946–1954.
168.
Dukers-MuijrersNHTMWolffsPLucchesiM, et al.Oropharyngeal Chlamydia trachomatis in women; spontaneous clearance and cure after treatment (FemCure). Sex Transm Infect2021; 97: 147–151.
169.
ManaviKHettiarachchiNHodsonJ. Comparison of doxycycline with azithromycin in treatment of pharyngeal chlamydia infection. Int J STD AIDS2016; 27: 1303–1308.
170.
SvenstrupHFDaveSSCarderC, et al.A cross-sectional study of Mycoplasma genitalium infection and correlates in women undergoing population-based screening or clinic-based testing for Chlamydia infection in London. BMJ Open2014; 4: e003947.
171.
MoiHReintonNMoghaddamA. Mycoplasma genitalium is associated with symptomatic and asymptomatic non-gonococcal urethritis in men. Sex Transm Infect2009; 85: 15–18.
172.
GetmanDJiangAO'DonnellM, et al.Mycoplasma genitalium prevalence, coinfection, and macrolide antibiotic resistance frequency in a multicenter clinical study cohort in the United States. J Clin Microbiol2016; 54: 2278–2283.
173.
GaydosCMaldeisNHardickA, et al.Mycoplasma genitalium compared to chlamydia, gonorrhoea and trichomonas as an aetiological agent of urethritis in men attending STD clinics. Sex Transm Infect2009; 85: 438–440.
174.
JensenJSCusiniMGombergM, et al.2021 European guideline on the management of Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol2022; 36: 641–650.
175.
MpigaPRavaoarinoroM. Effects of sustained antibiotic bactericidal treatment on Chlamydia trachomatis-infected epithelial-like cells (HeLa) and monocyte-like cells (THP-1 and U-937). Int J Antimicrob Agents2006; 27: 316–324.
176.
AmsdenGW. Erythromycin, clarithromycin, and azithromycin: are the differences real?Clin Ther1996; 18: 56.
177.
LodeHBornerKKoeppeP, et al.Azithromycin--review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother1996; 37(Suppl C): 1–8.
178.
UnemoMEndreKMMoiH. Five-day Azithromycin treatment regimen for Mycoplasma genitalium infection also effectively eradicates Chlamydia trachomatis. Acta Derm Venereol2015; 95: 730–732.
179.
CrossRLingCDayNP, et al.Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?Expet Opin Drug Saf2016; 15: 367–382.
180.
RossJGuaschinoSCusiniM, et al.2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS2018; 29: 108–114.
181.
PostemaEJRemeijerLvan der MeijdenWI. Epidemiology of genital chlamydial infections in patients with chlamydial conjunctivitis; a retrospective study. Genitourin Med1996; 72: 203–205.
182.
SulisGUrbinatiLFranzoniA, et al.Chlamydia trachomatis conjunctivitis in a male teenager: a case report. Infez Med2014; 22: 140–143.
183.
VaruDMRheeMKAkpekEK, et al.Conjunctivitis preferred practice Pattern®. Ophthalmology2019; 126: 94–169.
184.
TrelleSShangANarteyL, et al.Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review. BMJ2007; 334: 354.
185.
TheunissenKASchipperPHoebeCJ, et al.Barriers to and facilitators of partner notification for Chlamydia trachomatis among health care professionals. BMC Health Serv Res2014; 14: 647.
186.
LanjouwEOuburgSde VriesHJ, et al.2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS2016; 27: 333–348.
187.
OngJJBourneCDeanJA, et al.Australian sexually transmitted infection (STI) management guidelines for use in primary care 2022 update. Sex Health2023; 20: 1–8.
188.
RönnMMTuiteARMenziesNA, et al.The impact of screening and partner notification on Chlamydia prevalence and numbers of infections averted in the United States, 2000–2015: evaluation of epidemiologic trends using a pair-formation transmission model. Am J Epidemiol2019; 188: 545–554.
189.
NwokoloNCDragovicBPatelS, et al.2015 UK national guideline for the management of infection with Chlamydia trachomatis. Int J STD AIDS2016; 27: 251–267.
190.
van AarFvan BenthemBHBvan den BroekIVF, et al.STIs in sex partners notified for chlamydia exposure: implications for expedited partner therapy. Sex Transm Infect2018; 94: 619–621.
191.
PearceEChanDJSmithDE. Empiric antimicrobial treatment for asymptomatic sexual contacts of sexually transmitted infection in the era of antimicrobial resistance: time to rethink?Int J STD AIDS2019; 30: 137–139.
192.
RowlinsonEGoldenMRBerzkalnsA, et al.Epidemiologic treatment for contacts to Neisseria gonorrhoeae and Chlamydia trachomatis Infection in sexually transmitted disease clinic patients in Seattle, WA; 1994 to 2018. Sex Transm Dis2020; 47: 665–671.
193.
FrackeltonRJonesKHamerB, et al.Managing contacts of chlamydia: should clinics implement a test and wait process?Int J STD AIDS2021; 32: 38–44.
194.
FerreiraAYoungTMathewsC, et al.Strategies for partner notification for sexually transmitted infections, including HIV. Cochrane Database Syst Rev2013; 2013: CD002843.
195.
Centers for Disease Control and Prevention. Guidance on the use of expedited partner therapy in the treatment of gonorrhea. Centers for Disease Control and Prevention, 2021. https://www.cdc.gov/std/ept/gc-guidance.html, accessed31 December 2024.
196.
GoldenMRKeraniRPStengerM, et al.Uptake and population-level impact of expedited partner therapy (EPT) on Chlamydia trachomatis and Neisseria gonorrhoeae: the Washington State community-level randomized trial of EPT. PLoS Med2015; 12: e1001777.
197.
NanhoeACVisserMOmloJJ, et al.A pill for the partner via the chlamydia patient? Results from a mixed method study among sexual health care providers in The Netherlands. BMC Infect Dis2018; 18: 243.
198.
TiplicaGSRadcliffeKEvansC, et al.2015 European guidelines for the management of partners of persons with sexually transmitted infections. J Eur Acad Dermatol Venereol2015; 29: 1251–1257.
199.
Dionne-OdomJSubramaniamAAaronKJ, et al.High rates of persistent and recurrent chlamydia in pregnant women after treatment with azithromycin. Am J Obstet Gynecol MFM2020; 2: 100216.
200.
Dukers-MuijrersNHMorreSASpeksnijderA, et al.Chlamydia trachomatis test-of-cure cannot be based on a single highly sensitive laboratory test taken at least 3 weeks after treatment. PLoS One2012; 7: e34108.
201.
RenaultCAIsraelskiDMLevyV, et al.Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health2011; 8: 69–73.
202.
FungMScottKCKentCK, et al.Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect2007; 83: 304–309.
203.
HosenfeldCBWorkowskiKABermanS, et al.Repeat infection with chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis2009; 36: 478–489.
204.
HeijneJCHerzogSAAlthausCL, et al.Insights into the timing of repeated testing after treatment for Chlamydia trachomatis: data and modelling study. Sex Transm Infect2013; 89: 57–62.
205.
AghaizuAReidFKerryS, et al.Frequency and risk factors for incident and redetected Chlamydia trachomatis infection in sexually active, young, multi-ethnic women: a community based cohort study. Sex Transm Infect2014; 90: 524–528.
206.
Scott LamontagneDBasterKEmmettL, et al.Incidence and reinfection rates of genital chlamydial infection among women aged 16–24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia recall study advisory group. Sex Transm Infect2007; 83: 292–303.
MolinaJMCharreauIChidiacC, et al.Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis2018; 18: 308–317.
209.
MolinaJMBercotBAssoumouL, et al.Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design. Lancet Infect Dis2024; 24: 1093–1104.
210.
LuetkemeyerAFDonnellDDombrowskiJC, et al.Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med2023; 388: 1296–1306.
211.
SherrardJGokenginDWinterA, et al.IUSTI Europe position statement on use of DoxyPEP: june 2024. Int J STD AIDS2024; 35: 1087–1089.
